3-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine | 1223081-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 3-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine
• CAS: 1223081-91-1
• 化学式: C₁₂H₁₅N₅
• 分子量: 229.285
• InChiKey: RLUYDECZUYNLIA-ILWJIGKKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  17.0
• 可旋转键数：
  1.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  55.63
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  3-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine 、 (S)-4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxo-3-phenylbutanal 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (S)-3-((S)-4-((1R,3R,5S)-3-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-phenylbutanoyl)-4-benzyloxazolidin-2-one
  参考文献：
  名称：

  Discovery of novel (S)-α-phenyl-γ-amino butanamide containing CCR5 antagonists via functionality inversion approach

  摘要：

  By using functionality inversion approach, we identified a new scaffold containing (S)-alpha-phenyl-gamma-amino butanamide as CCR5 antagonists derived from the 1,3-propanediamine carboxamide pharmacophore protocol. The (2S)-2-phenyl-4-(8-aza-bicyclo[3.2.1]octan-8-yl)-butanamide derivatives display significantly high potency to antagonize CCR5 receptor with nanomolar IC50 values. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.023
• 作为产物：
  描述：

  ethyl (1R,3s,5S)-3-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate 在 盐酸 、 水 作用下， 反应 10.0h， 生成 3-((1R,3s,5S)-8-azabicyclo[3.2.1]octan-3-yl)-3H-[1,2,3]triazolo[4,5-b]pyridine
  参考文献：
  名称：

  Discovery of novel (S)-α-phenyl-γ-amino butanamide containing CCR5 antagonists via functionality inversion approach

  摘要：

  By using functionality inversion approach, we identified a new scaffold containing (S)-alpha-phenyl-gamma-amino butanamide as CCR5 antagonists derived from the 1,3-propanediamine carboxamide pharmacophore protocol. The (2S)-2-phenyl-4-(8-aza-bicyclo[3.2.1]octan-8-yl)-butanamide derivatives display significantly high potency to antagonize CCR5 receptor with nanomolar IC50 values. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.023